Effect of pioglitazone, quercetin and hydroxy citric acid on extracellular matrix components in experimentally induced non-alcoholic steatohepatitis
- PMID: 26557974
- PMCID: PMC4633468
Effect of pioglitazone, quercetin and hydroxy citric acid on extracellular matrix components in experimentally induced non-alcoholic steatohepatitis
Abstract
Objectives: Non-alcoholic steatohepatitis (NASH), is an important component of Non-alcoholic fatty liver disease (NAFLD) spectrum, which progresses to the end stage liver disease, if not diagnosed and treated properly. The disproportionate production of pro- and anti-inflammatory adipokines secreted from fat contributes to the pathogenesis of NASH. In this study, the comparative effect of pioglitazone, quercetin and hydroxy citric acid on extracellular matrix (ECM) component levels were studied in experimentally induced NASH.
Materials and methods: The experimental protocol consists of using 48 male Wister rats, which were divided into 8 groups. The levels of hyaluronic acid, leptin and adiponectin were monitored in experimental NASH.
Results: The experimental NASH rats treated with pioglitazone showed significant decrease in the levels of hyaluronic acid and significant increase in adiponectin levels when compared to experimentally induced NASH group, but did not show any effect on the levels of leptin. Contrary to these two drugs, viz. pioglitazone and hydroxy citric acid, the group treated with quercetin showed significant decrease in the levels of hyaluronic acid and leptin and significant decrease in adiponectin levels compared with that of experimentally induced NASH NASH group, offering maximum protection against NASH.
Conclusion: Considering our findings, it could be concluded that quercetin may offer maximum protection against NASH by significantly increasing the levels of adiponectin, when compared to pioglitazone and hydroxy citric acid.
Keywords: Adiponectin; Hyaluronic acid; Hydroxy citric acid; Leptin; Non-alcoholic fatty liver –; Non-alcoholic–steatohepatitis (NASH); Pioglitazone; Quercetin; disease (NAFLD).
Similar articles
-
Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH).Eur Rev Med Pharmacol Sci. 2014;18(18):2736-41. Eur Rev Med Pharmacol Sci. 2014. PMID: 25317811
-
Pioglitazone, quercetin and hydroxy citric acid effect on hepatic biomarkers in Non Alcoholic Steatohepatitis.Pharmacognosy Res. 2014 Apr;6(2):153-62. doi: 10.4103/0974-8490.129037. Pharmacognosy Res. 2014. PMID: 24761121 Free PMC article.
-
Comparative effect of pioglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis.J Physiol Pharmacol. 2014 Feb;65(1):67-74. J Physiol Pharmacol. 2014. PMID: 24622831
-
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4. Metabolism. 2017. PMID: 28521870 Review.
-
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.Diabetologia. 2016 Jun;59(6):1112-20. doi: 10.1007/s00125-016-3952-1. Epub 2016 Apr 21. Diabetologia. 2016. PMID: 27101131 Free PMC article. Review.
Cited by
-
Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications.Saudi J Gastroenterol. 2021 Nov-Dec;27(6):319-330. doi: 10.4103/sjg.sjg_249_21. Saudi J Gastroenterol. 2021. PMID: 34810376 Free PMC article. Review.
-
The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease.Clin Exp Hepatol. 2017 Sep;3(3):127-134. doi: 10.5114/ceh.2017.68466. Epub 2017 Jun 21. Clin Exp Hepatol. 2017. PMID: 29062902 Free PMC article. Review.
-
Comparative In Vitro Evaluation of Antibacterial and Osteogenic Activity of Polysaccharide and Flavonoid Fractions Isolated from the leaves of Saussurea controversa.Molecules. 2019 Oct 12;24(20):3680. doi: 10.3390/molecules24203680. Molecules. 2019. PMID: 31614835 Free PMC article.
-
Herbal medicines and nonalcoholic fatty liver disease.World J Gastroenterol. 2016 Aug 14;22(30):6890-905. doi: 10.3748/wjg.v22.i30.6890. World J Gastroenterol. 2016. PMID: 27570425 Free PMC article. Review.
-
Thiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearoyl-CoA desaturase-1, lipase activity, leptin and resistin.Exp Ther Med. 2018 Oct;16(4):2938-2948. doi: 10.3892/etm.2018.6563. Epub 2018 Aug 2. Exp Ther Med. 2018. PMID: 30214514 Free PMC article.
References
-
- Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–438. - PubMed
-
- Ahmed MH, Byrne CD. Non-alcoholic steatohepatitis. In: Byrne CD, D Wild S, editors. Metabolic syndrome. Chichester: John Wiley & Sons; 2005. pp. 279–305.
-
- Liou I, Kowdley KV. Natural history of nonalcoholic-steatohepatitis. J ClinGastroenterol. 2006;40:S11–16. - PubMed
-
- Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048–1058. - PubMed
LinkOut - more resources
Full Text Sources